Skip to content

US · AIXC · MEDICAL - PHARMACEUTICALS

AIxCrypto Holdings, Inc. (AIXC) intrinsic value and stock valuation

$1.37as of 2026-11-21 · Mkt cap 3.98M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AIxCrypto Holdings, Inc. DCF and intrinsic value

InvestorsCraft values AIXC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AIXC’s statements →

AIxCrypto Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Carlsbad, CA 92008 aixcrypto.ai

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-16.97M
20122025
Free cash flow
-$-23.54M
20122025
Total equity
$28M+8.9% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$5.65M
Operating income-$-13.2M-$-5.76M-$-11.3M-$-14.76M-$-22.66M
Net income-$-16.97M-$-6.26M-$-13.42M-$-18.64M-$-17.9M
EPSd-$-7.04M-$-17.39M-$-134.2M-$-233M-$-298.33M
Operating cash flow-$-6.95M-$-6.33M-$-10.3M-$-13.25M-$-14.73M
Capital expenditure-$-16.59M$0.00$0.00-$-320K-$-140K
Free cash flow-$-23.54M-$-6.33M-$-10.3M-$-13.57M-$-14.87M
Total assets$31.3M$4.69M$2.03M$19.1M$22.8M
Total debt$140K$0.00$1.3M$1.76M$1.68M
Net debt-$-19.19M-$-1.17M$900K-$-1.41M-$-15.86M
Total equity$28M$2.68M-$-2.1M$8.77M$16.6M
Cash and short-term investments$19.3M$1.17M$400K$3.17M$17.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$5.65M
Cost of revenue$0.00$0.00$0.00$10K$4.33M
Gross profit$0.00$0.00$0.00-$-10K$1.32M
Research and development expenses$180K$1.2M$5.21M$4.49M$11.7M
Selling, general and administrative expenses$8.82M$4.2M$6.1M$10.3M$12.3M
Other expenses$4.2M$360K-$-5.21M-$-10K$0.00
Operating expenses$13.2M$5.76M$11.3M$14.8M$24M
Cost and expenses$13.2M$5.76M$11.3M$14.8M$28.3M
Interest income$740K$130K$0.00$0.00$0.00
Interest expense$990K$910K$1.52M$30K$0.00
Depreciation and amortization$0.00$0.00$0.00$10K$340K
Ebitda-$-15.98M-$-5.24M-$-10.95M-$-13.84M-$-22.32M
Operating income-$-13.2M-$-5.76M-$-11.3M-$-14.76M-$-22.66M
Total other income/expenses, net-$-3.76M-$-390K-$-1.17M$870K$4.77M
Income before tax-$-16.97M-$-6.15M-$-12.48M-$-13.89M-$-17.89M
Income tax expense$0.00$10K-$0.00$10K$10K
Net income-$-16.97M-$-6.26M-$-13.42M-$-18.64M-$-17.9M
Weighted average shares outstanding$2.41M$360K$100K$80K$60K
Weighted average diluted shares outstanding$2.41M$360K$100K$80K$60K
Balance sheet
20252024202320222021
Cash and short-term investments$19.3M$1.17M$400K$3.17M$17.5M
Net receivables$340K$2.01M$0.00$540K$820K
Inventory$0.00$0.00$0.00$1.59M$1.06M
Total current assets$31M$4.68M$1.17M$10.8M$20.8M
Property, plant and equipment, net$0.00$0.00$0.00$30K$1.85M
Goodwill and intangible assets$310K$0.00$0.00$6.47M$170K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$330K$0.00$870K$8.26M$2.04M
Total assets$31.3M$4.69M$2.03M$19.1M$22.8M
Accounts payable$1.26M$1.57M$2.22M$620K$890K
Short-term debt$140K$0.00$1.3M$460K$130K
Deferred revenue$0.00$0.00$0.00$120K$140K
Total current liabilities$3.33M$2.01M$4.14M$8.61M$4.64M
Long-term debt$0.00$0.00$0.00$1.3M$1.54M
Deferred revenue, non-current$0.00$0.00$0.00$50K$90K
Total non-current liabilities$0.00$0.00$0.00$1.71M$1.64M
Capital lease obligations$0.00$0.00$0.00$1.7M$1.68M
Total liabilities$3.33M$2.01M$4.14M$10.3M$6.27M
Common stock$70K$70K$40K$40K$40K
Retained earnings-$-140.03M-$-123.06M-$-116.8M-$-103.39M-$-84.74M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$50K$0.00
Total equity$28M$2.68M-$-2.1M$8.77M$16.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$140K$0.00$1.3M$1.76M$1.68M
Net debt-$-19.19M-$-1.17M$900K-$-1.41M-$-15.86M
Cash flow statement
20252024202320222021
Net income-$-16.97M-$-6.16M-$-12.48M-$-13.89M-$-17.9M
Depreciation and amortization$0.00$0.00$0.00$10K$340K
Stock-based compensation$0.00$130K$1.1M$4.77M$5.29M
Change in working capital$1.55M-$-780K$1.11M-$-640K$2.21M
Accounts receivable$0.00$0.00$0.00$420K$40K
Inventory$0.00$0.00$0.00-$-640K$110K
Accounts payable-$-350K-$-450K$1.6M-$-40K$390K
Net cash provided by operating activities-$-6.95M-$-6.33M-$-10.3M-$-13.25M-$-14.73M
Investments in property, plant and equipment-$-16.59M$0.00$0.00-$-320K-$-130K
Acquisitions, net$0.00$0.00$0.00$140K$0.00
Net cash used for investing activities-$-15.88M-$-1.91M$4.22M-$-180K-$-140K
Common stock issued$34.2M$3.05M$0.00$0.00$8.82M
Common stock repurchased$0.00$0.00$0.00-$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$41M$9.01M-$-550K$2.91M$8.43M
Net change in cash$18.2M$770K-$-6.64M-$-14.37M-$-6.44M
Cash at end of period$19.3M$1.17M$400K$3.17M$17.5M
Operating cash flow-$-6.95M-$-6.33M-$-10.3M-$-13.25M-$-14.73M
Capital expenditure-$-16.59M$0.00$0.00-$-320K-$-140K
Free cash flow-$-23.54M-$-6.33M-$-10.3M-$-13.57M-$-14.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AIxCrypto Holdings, Inc.

        AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

        CEO
        Jiawei Wang
        Employees
        4
        Beta
        0.49

        Explore

        Frequently asked questions

        What is the intrinsic value of AIxCrypto Holdings, Inc. (AIXC)?

        InvestorsCraft does not currently publish an intrinsic value for AIXC. How the IC value is calculated.

        Is AIXC undervalued?

        InvestorsCraft does not publish an undervaluation signal for AIXC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.